Patient Deaths in China Trials Spur U.S. Demand for FDA Scrutiny

U.S. House lawmakers say the FDA should not rely on Chinese clinical-trial data without recent inspections, citing opaque reporting of serious adverse events in high-risk biomedical research

Raccontata dacaixinglobal.com